---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-001239"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:09:05.204343+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma licenses mavorixafor to Norgine for €28.5M upfront, up to €226M milestones

## Summary
- Exclusive license for Europe, Switzerland, UK, Australia, New Zealand; X4 retains rest of world.
- X4 receives €28.5M upfront; up to €226M in regulatory, commercial, sales milestones.
- Escalating double-digit royalties up to mid-twenties on net sales in licensed territories.
- X4 continues Phase 3 4WARD trial in chronic neutropenia; Norgine handles commercialization.
- MAA for WHIM syndrome to be submitted to EMA shortly; mavorixafor has Orphan Drug Designation.

## SEC filing metadata
- accession: 0001628280-25-001239
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828025001239/0001628280-25-001239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828025001239/xfor-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-001239
- JSON: https://secwatch.observer/filing/0001628280-25-001239.json
- Plain text: https://secwatch.observer/filing/0001628280-25-001239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.